Company Overview and News

 
Apollo Hospitals Enterprise Limited - Trading Window

2018-05-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Apollo Hospitals Enterprise Limited - Updates

2018-05-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Clouds over Indian hospital chain Fortis keep suitors from making higher bids

2018-04-23 reuters
MUMBAI/BENGALURU (Reuters) - India’s Fortis Healthcare Ltd (FOHE.NS) has received as many as five offers for control of its private hospital business, but suitors have so far held back from making bold bids for the group as it faces rising debt and a regulatory probe.

 
Closing Bell: Nifty manages to hold 10,400, Sensex ends higher for 5th day

2018-04-11 moneycontrol
3:30 pm Market Closing: Benchmark indices closed higher for fifth consecutive session on Wednesday. The 30-share BSE Sensex was up 60.19 points at 33,940.44 and the 50-share NSE Nifty rose 14.90 points to 10,417.20.

 
Market Live: Nifty hovers around 10,400; PSU Bank dips 2%, RIL extends gains

2018-04-11 moneycontrol
2:50 pm Europe Lower: Equities in Europe moved lower as investors began to focus on earnings at the start of a new reporting season.

 
Fortis-Manipal deal still a 50:50 bet, says Ranjan Pai

2018-04-09 livemint
Mumbai: The sale of Fortis Healthcare Ltd’s hospital assets to a Manipal Health Enterprises Pvt Ltd-TPG Capital combine can still swing either way with a 50% probability of the deal going through, said the managing director and chief executive at Manipal Health in an interview.

 
Fortis sells hospital business to Manipal, TPG Capital

2018-03-27 livemint
Mumbai: After months of intense negotiations, the board of Fortis Healthcare Ltd late on Tuesday night announced the sale of its hospital assets to Manipal Health Enterprises Pvt. Ltd and buyout firm TPG Capital.

 
Apollo Hospitals Enterprise Limited - Updates

2018-03-22 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Apollo Hospitals Enterprise Limited - Updates

2018-03-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
KKR arm gives Rs425 crore credit to promoters of KPIT to fund open offer

2018-03-04 livemint
Mumbai: An Indian unit of global private equity leader KKR and Co. has provided Rs425 crore in structured credit to the promoters of KPIT Technologies Ltd to finance an open offer for the company, two people aware of the development said.

 
Apollo Hospitals Enterprise Limited - Updates

2018-02-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Apollo Hospitals Enterprise Limited - Updates

2018-02-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Apollo Hospitals Q3 net down 7.40 %

2018-02-15 thehindubusinessline
Apollo Hospitals Enterprise today reported a 7.4 per cent decline in standalone net profit at ₹ 67.44 crore for the third quarter ended December 31, 2017 on account of higher expenses.

 
Apollo Hospitals Q3 net down 7.4 % to Rs 67 crore

2018-02-14 moneycontrol
Apollo Hospitals Enterprise on Wednesday reported a 7.4 percent decline in standalone net profit at Rs 67.44 crore for the third quarter ended December 31, 2017 on account of higher expenses.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

23h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

23h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...